NHC CEO Myrl Weinberg will participate in Stakeholder Prespectives on the Future of the Sentinel System from 11:15 to 12:30. The event has reached in-person capacity. Please click here to attend via webcast.
The Food and Drug Administration Amendments Act of 2007 mandated that the U.S. Food and Drug Administration (FDA) develop a national electronic system to track the safety of regulated medical products. In response, FDA launched the Sentinel Initiative in 2008. Mini-Sentinel, a pilot project of the Sentinel Initiative, uses electronic health care data for postmarket risk identification and analysis of medical product safety.
On February 5, the Engelberg Center for Health Care Reform at Brookings will host the seventh annual Sentinel Initiative Public Workshop at the Washington Plaza Hotel in Washington, DC. This event will serve as a forum for leading experts and stakeholders to discuss the current state of the Mini-Sentinel activities; explore stakeholder perspectives on the future of Sentinel; and identify opportunities to expand its use. Dr. Janet Woodcock, the Director of the Center for Drug Evaluation and Research at FDA, will provide the morning keynote address.
This group, made up of the senior government relations staff from member patient advocacy organizations (also known as voluntary health agencies or VHAs), helps set the NHC policy agenda and promotes the exchange of ideas and sharing of common solutions among members. All meetings will be held at the NHC’s office at 1730 M St. NW, Suite 500.